Disease Modification in Parkinson's: What It Means and What's Coming Next

Learn more about Parkinson's and find support: https://dpf.org

Researchers are exploring a growing number of potential disease-modifying therapies for Parkinson's. But what does "disease-modifying" actually mean, and what progress is being made?

In this podcast, Chris Krueger of the Davis Phinney Foundation talks with Dr. Lorraine Kalia, a neurologist and Parkinson's researcher, about the science behind disease modification and why finding therapies that change the course of Parkinson's is so challenging.

Topics discussed include research targeting alpha-synuclein, inflammation, genetics, mitochondria, gene therapy, and stem cells, while also addressing common questions about experimental and unproven treatments. Dr. Kalia closes with a hopeful message: while researchers continue working toward tomorrow's breakthroughs, there are meaningful steps people with Parkinson's can take today to support their health, well-being, and quality of life.

This episode was produced with support from AskBio.

Speaker Bio:

Lorraine Kalia, MD, PhD, FRCPC is a scientist at the Toronto Western Research Institute and Tanz Centre for Research in Neurodegenerative Diseases. She is also a neurologist specializing in Parkinson's disease and related movement disorders at the Toronto Western Hospital. She is an assistant professor in the Division of Neurology, Department of Medicine at the University of Toronto.

Sign up for updates on webinars, events, and resources for the Parkinson's community: https://dpf.org/newsletter-signup